NTLA originally thought the FDA lift would bring some decent performance, but it's still being suppressed. The gene editing logic has been really tough lately, lacking the courage to cut losses, and holding on is painful.
For stocks like NUWE that suddenly surge 100% with no news, I'd rather just watch from afar. Nowadays, it's all about robot trading.
FEED directly doubled, supported by the distribution agreement. It might stay hot for a while based on news, but 冷静下来想想，these days you need to ride some hype to get any action.
Small-cap pharma stocks each have their own volatility drama—who laughs last is really up to fate.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
